VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism, which has completed phase 3 clinical trial. It has strategic collaboration agreements with Shanghai Pharmaceutical, XtalPi, Anke Bio, and the United Family Healthcare. VISEN Pharmaceuticals was incorporated in 2018 and is headquartered in Suzhou, China.
Frequently asked questions
What sector does VISEN Pharmaceuticals (2561) operate in?
VISEN Pharmaceuticals belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is VISEN Pharmaceuticals (2561) current stock price?
As of the latest data, VISEN Pharmaceuticals stock price is HK$15.00, with a previous close of HK$15.50. VISEN Pharmaceuticals lost -HK$0.50 in the last trading session, representing a -3.23% loss.
What is VISEN Pharmaceuticals (2561) current market capitalization?
VISEN Pharmaceuticals market cap is approximately 1.64 billion.
What is VISEN Pharmaceuticals (2561) EBITDA?
VISEN Pharmaceuticals EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -50.14 million.
Does VISEN Pharmaceuticals (2561) pay dividends?
No. VISEN Pharmaceuticals does not pay a dividend.
What is VISEN Pharmaceuticals (2561) beta (volatility) score?
VISEN Pharmaceuticals has a beta of 0.021, indicating lower volatility than the overall market.
